Oral Mucositis (Ulcerative) Clinical Trial
Official title:
Efficacy of Bioptron Light Therapy (BLT) on Post Chemotherapy Oral Mucositis
The study aimed to study the effect of Bioptron light therapy (BLT) on oral mucositis after
receiving chemotherapy in patients with head and neck cancer,Oral mucositis (OM) is a common
and severe acute side-effect of many oncologic treatments, especially in patients treated for
head and neck cancer. It affects quality of life and require supportive care and proper
treatment plane.
This study had been conducted on thirty cancer patients (head &neck) receiving chemotherapy &
radiotherapy (males and females) with oral mucositis with ulceration and pain(grade 2 and
more), their age ranged from 35 to 55 years, capable of understanding the study assessment
method and willing to complete the current study, they were free from any immunodeficiency
disorders or diseases that could impair the healing process and impact the results as
diabetes mellitus. Patients were randomly allocated from patients from the National Cancer
Institute, Cairo University. Group A (BLT group): This group consisted of 15 patients
receiving BLT for about 10 minutes every day for thirty days in addition to routine oral
mucositis medical care (Analgesics, anti-inflammatory treatment and antimicrobial treatment
for any new mouth infections), Group B (Control group): This group consisted of 15 patients
receiving daily routine oral mucositis medical care(Analgesics, anti-inflammatory treatment
and antimicrobial treatment for any new mouth infections) for thirty days The methods of
evaluation in the current study were the WHO oral mucositis scale (OMS) and the Common
toxicity criteria scale (CTCS). At the same time, the treatment equipment was the polarized
light therapy device Bioptron Compact III (PAG-860 manufactured in Switzerland) Assessment by
WHO oral mucositis scale and (OMS) and (CTCS) were used before treatment and after treatment
to measure improvement in oral mucositis.
The results of WHO oral mucositis scale (OMS) and the Common toxicity criteria scale (CTCS)
were assessed first at the beginning of the study and one month after the end of the study;
calculation of mean, standard deviation, minimum and maximum for each group was done by
descriptive statistics, means comparison between the two groups pre and post-application and
within each group was made using The t-test. With a level of significance Alpha point of 0.05
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04870060 -
Ability of Curcumin to Decrease Cytokines Involved in Mucositis in the Autologous Transplant
|
Phase 2 | |
Completed |
NCT05018754 -
Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF
|
||
Recruiting |
NCT04896164 -
Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting
|
Phase 3 | |
Active, not recruiting |
NCT03972527 -
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
|
N/A |